Molecular Diagnostics (MDx) is the detection of nucleic acid (DNA or RNA) for the purposes of pathogen detection, disease diagnosis, susceptibility testing and prognosis. The total value of the clinical MDx market is expected to be more than $5 billion in 2011, and is the fastest growing segment of the in vitro diagnostics business.
The majority of tests are used for the detection and measurement of infectious bacteria and viruses, with around 90% of them being performed in centralised laboratories in USA, EU and Japan. Much of the growth is being driven by the identification of new microbiological targets, adoption of new tests for human genetics and oncology, and wider usage in emerging markets.
Lumora’s development efforts are directed to areas where the features of BART – robust, affordable, easy-to-use - can offer the most significant benefits compared to existing platforms, enabling more healthcare professionals access to the vital information they need to make rapid, accurate decisions. Some of the key areas of focus are: